Anzeige
Mehr »
Freitag, 04.07.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C2EY | ISIN: US04635X1028 | Ticker-Symbol: 2090
NASDAQ
03.07.25 | 18:40
5,790 US-Dollar
+1,22 % +0,070
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
ASTRIA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ASTRIA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
4,7805,00019:00

Aktuelle News zur ASTRIA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.06.Astria Therapeutics, Inc.: Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress275-- Q3M Arm Demonstrated 95% Mean Monthly Attack-Rate Reduction -- -- Q6M Arm Demonstrated 86% Mean Monthly Attack-Rate Reduction - -- Well-Tolerated with a Favorable Safety Profile -- --...
► Artikel lesen
ASTRIA THERAPEUTICS Aktie jetzt für 0€ handeln
06.06.Astria Therapeutics, Inc.: Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress288Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present four...
► Artikel lesen
04.06.Astria Therapeutics bei Jefferies-Konferenz: Strategische Pipeline-Einblicke10
29.05.Citizens JMP hält an Kursziel von 25 US-Dollar für Astria Therapeutics-Aktie fest34
29.05.Citizens JMP maintains $25 target on Astria Therapeutics stock6
23.05.Astria Therapeutics, Inc.: Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop324Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present at...
► Artikel lesen
14.05.JMP cuts Astria Therapeutics target to $25, maintains rating9
13.05.Astria TherapeuticS GAAP EPS of -$0.58 misses by $0.103
13.05.Astria Therapeutics, Inc. - 10-Q, Quarterly Report4
01.05.Astria Therapeutics meldet Fortschritte bei HAE-Medikamentenstudie17
01.05.Astria Therapeutics reports progress in HAE drug trial3
11.03.Astria Therapeutics, Inc. - 10-K, Annual Report3
11.03.Astria TherapeuticS GAAP EPS of -$1.68 beats by $0.014
11.03.Astria Therapeutics, Inc. - 8-K, Current Report1
28.02.Astria Therapeutics, Inc.: Astria Therapeutics beginnt Phase-3-Zulassungsstudie ALPHA-ORBIT zu Navenibart bei hereditärem Angioödem462-- Studie zum Nachweis der Wirksamkeit und Sicherheit der Verabreichung alle 3 und alle 6 Monate in einem 6-monatigen Behandlungszeitraum -- Astria Therapeutics, Inc. (Nasdaq: ATXS), ein biopharmazeutisches...
► Artikel lesen
18.02.JMP SECURITIES REITERATES ASTRIA THERAPEUTICS OUTPERFORM RATING20
13.01.Astria Therapeutics, Inc. - 8-K, Current Report9
13.11.24Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update277BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported...
► Artikel lesen
13.11.24Astria Therapeutics, Inc.: Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference313Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D....
► Artikel lesen
27.09.24Astria Therapeutics, Inc.: Astria Therapeutics to Present at Upcoming Global Angioedema Forum558Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that leading HAE experts...
► Artikel lesen
Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1